[{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"I-131 Iopofosine","moa":"AKT1","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"Meaningful Insights-BioTech Analytics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Partnership","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectar \/ Meaningful Insights-BioTech Analytics","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Meaningful Insights-BioTech Analytics"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"Rosalind Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Private Placement","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Cellectar \/ Rosalind Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Rosalind Advisors"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Funding","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectar \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Cellectar","sponsor":"Evergreen Theragnostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellectar \/ Cellectar","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Cellectar"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"NOV-205","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CLR131","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CLR131","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Cellectar \/ National Cancer Institute"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"124-I CLR1404","moa":"Tumor cell membrane protein-phosphatidyl serine","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2011","type":"Inapplicable","leadProduct":"131-I CLR1404","moa":"Tumor cell membrane protein-phosphatidyl serine","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2014","type":"Inapplicable","leadProduct":"131-I CLR1404","moa":"Tumor cell membrane protein-phosphatidyl serine","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2025","type":"Agreement","leadProduct":"225-Ac CLR 121225","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Cellectar","highestDevelopmentStatusID":"4","companyTruncated":"Cellectar \/ Cellectar"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CLR 121225","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"CLR 121225","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Cellectar","highestDevelopmentStatusID":"4","companyTruncated":"Cellectar \/ Cellectar"},{"orgOrder":0,"company":"Cellectar","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Public Offering","leadProduct":"CLR 125","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectar","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Cellectar \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Cellectar","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Public Offering","leadProduct":"CLR 125","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectar","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Cellectar \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Cellectar","sponsor":"Nusano","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Agreement","leadProduct":"CLR 125","moa":"Ionising radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Cellectar","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Cellectar"},{"orgOrder":0,"company":"Cellectar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"I-131 CLR1404","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellectar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Undisclosed"},{"orgOrder":0,"company":"Cellectar","sponsor":"IntoCell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Cellectar","highestDevelopmentStatusID":"1","companyTruncated":"Cellectar \/ Cellectar"},{"orgOrder":0,"company":"Cellectar","sponsor":"Evestia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2025","type":"Agreement","leadProduct":"CLR 125","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Cellectar","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Cellectar"},{"orgOrder":0,"company":"Cellectar","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Private Placement","leadProduct":"CLR 125","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectar","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Cellectar \/ Ladenburg Thalmann & Co"}]
Find Clinical Drug Pipeline Developments & Deals by Cellectar
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
